A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Small Cell Glioblastoma
Giant Cell Glioblastoma
Gliosarcoma
Glioblastoma With Oligodendroglial Component
Recurrent Glioblastoma
Relapsed Glioblastoma

Interventions

DRUG: Bevacizumab
DRUG: Rindopepimut (CDX-110) with GM-CSF
DRUG: KLH

Sponsor

Celldex Therapeutics